-
Oppenheimer Raises PT On QCOR To $35
Wednesday, July 27, 2011 - 8:18am | 153Oppenheimer is maintaining its Outperform rating and is raising its price target from $27 to $35 on Questcor Pharmaceuticals (NASDAQ: QCOR) as the company continues to exceed expectations. In the report, Oppenheimer states, “On 7/26, QCOR reported 2Q11 adj. EPS of $0.23, above our $0.17 estimate...
-
Oculus Innovative Sciences Announces a Multi-Year Licensing Agreement With Eloquest Healthcare for Microcyn-Based Wound Care Products
Wednesday, July 27, 2011 - 8:13am | 199Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), today announced a multi-year licensing agreement with Eloquest Healthcare, a wholly owned subsidiary of Ferndale Pharma Group, Inc., to market multiple Microcyn®-based products in the United States under the Eloquest Healthcare brand, including...
-
UPDATE: Mylan Reports Stronger-Than-Expected Q2 Results
Wednesday, July 27, 2011 - 7:30am | 72Mylan Inc (NASDAQ: MYL) reported a 70% rise in its second-quarter earnings. Mylan reported its quarterly profit at $146.4 million, or $0.33 per share, up from $86.2 million, or $0.16 per share, in the year-ago period. Excluding items, Mylan's earnings came in at $0.52 per share. Its revenue...
-
Meda Denies Takeover Bid from Valeant
Wednesday, July 27, 2011 - 7:20am | 51Swedish drugmaker Meda said on Wednesday it had not received a takeover bid from Valeant Pharmaceuticals (NYSE: VRX). The Wall Street Journal said on Tuesday a "source" had told them Valeant had made an informal offer to Meda valued at more than $4 billion.
-
Columbia Laboratories Licenses STRIANT Canadian Trademark and Marketing Rights to Invaron Pharmaceuticals Inc.
Wednesday, July 27, 2011 - 6:53am | 79Columbia Laboratories, Inc. (Nasdaq: CBRX) has entered into a license agreement with Invaron Pharmaceuticals Inc., a privately-held Canadian pharmaceutical company, for STRIANT in Canada. Under the terms of the agreement, Invaron will seek regulatory approval for and will market STRIANT in Canada...
-
UPDATE: Teva Pharmaceutical Reports Upbeat Q2 Profit
Wednesday, July 27, 2011 - 6:49am | 82Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) reported upbeat quarterly earnings. TEVA reported its Q2 non-GAAP net income at $984 million, up from $981 million, in the year-ago period. Its earnings on a non-GAAP basis came in at $1.10 per share, up from $1.08 per share. Analysts were...
-
Oppenheimer Raises PT On Questcor Pharmaceuticals To $35
Wednesday, July 27, 2011 - 6:45am | 26Oppenheimer has raised the price target on Questcor Pharmaceuticals (NASDAQ: QCOR) from $27 to $35 and maintains its Outperform rating.
-
Stocks to Watch for Wednesday 7/27/2011: Fresh 52 Week Highs and Lows
Wednesday, July 27, 2011 - 4:37am | 2249Stocks trading at or near 52-week highs and lows provide excellent trading opportunities, as volatility tends to increase at such levels and exit/entry points become more clearly defined. The following stocks hit new 52-week highs in Tuesday's trading session (listed from highest total volume to...
-
Watson Enters into Agreement to Acquire Products Related to Perrigo's Acquisition of Paddock Laboratories; Terms Undisclosed
Tuesday, July 26, 2011 - 4:31pm | 108Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories. The portfolio consists of six products, including four FDA-...
-
Earnings Preview: Merck EPS, Revenue Expected to Rise from Previous Quarter
Tuesday, July 26, 2011 - 1:00pm | 570Merck (NYSE: MRK) announces its next round of earnings this Friday, July 29, 2011. Here is Benzinga's everything-that-matters guide for this Friday's second quarter earnings announcement. Earnings and Revenue: Based on estimates, investors are readying for a positive EPS reading of 95 cents...
-
Amgen Earnings Preview: Analysts Expect Rising Revenue, Falling EPS Over Previous Quarter
Tuesday, July 26, 2011 - 12:29pm | 562Amgen (NASDAQ: AMGN) unveils its next round of earnings this Friday, July 29, 2011. Here's Benzinga's advanced look at Amgen's second quarter earnings report. Earnings and Revenue: Wall Street expects an EPS of $1.30 per share and revenues of $3.78 billion. Amgen's latest numbers will no...
-
First Global Reiterates LT Outperform Rating on Abbott Inc
Tuesday, July 26, 2011 - 10:08am | 194First Global has published a report on Abbott Inc (NYSE: ABT) reviewing the last quarter. In the report, First Global wrote, "Abbott Inc. (ABT) came up with a strong show in Q2 CY11, with the company delivering a sales out performance across all its major businesses and its reported EPS for the...
-
GlaxoSmithKline Hits New 52-Week High at $45.10 after Earnings this Morning
Tuesday, July 26, 2011 - 9:34am | 75Many traders and investors see the 52-week high or low as an important indicator. Stocks that have a long-term trend in a certain direction are likely to continue, as that trend is the path of least resistance. In this case, shares of GlaxoSmithKline (NYSE: GSK) are hitting new 52-week highs....
-
Earnings Roundup
Tuesday, July 26, 2011 - 9:32am | 1635Lockheed Martin Corp (NYSE: LMT) reported a 10% decline in its Q2 profit. Lockheed Martin's quarterly net earnings dropped to $742 million, or $2.14 per share, from $824 million, or $2.22 per share, in the year-earlier quarter. Its net sales increased to $11.55 billion from $11.28 billion....
-
Morgan Stanley Comments on Allergan After Migraine Survey
Tuesday, July 26, 2011 - 8:57am | 173Morgan Stanley has published a report on Allergan (NYSE: AGN) after a Botox migraine survey was conducted. In the report Morgan Stanley wrote, "Our AlphaWise survey of 350 neurologists suggests that Botox migraine penetration may be faster than we project, but patient pool may be smaller, yielding...